市场调查报告书
商品编码
1261169
BNP和NT-proBNP全球市场规模,份额,行业趋势分析报告,按测试地点,应用(心肌梗塞,急性冠状动脉综合征(ACS),充血性心力衰竭(CHF)),地区展望和预测,2022-2028 年Global Bnp and Ntprobnp Market Size, Share & Industry Trends Analysis Report By Location of Testing, By Application (Myocardial Infarction, Acute Coronary Syndrome (ACS), Congestive Heart Failure (CHF)), By Regional Outlook and Forecast, 2022 - 2028 |
BNP 和 NT-proBNP 市场规模预计将在 2028 年达到 22 亿美元,预测期内市场复合年增长率为 11.4%。
但是,高水平可能表明心臟没有为身体提供足够的血液。 在这种情况下会发生心力衰竭,有时称为充血性心力衰竭。 利钠□测定法测量血液中 NT-proBNP 或 BNP 的浓度。 两者都有不同的参数,所有这些都可用于诊断心力衰竭。 选项用户将依赖提供商提议的实验室拥有的工具。
BNP 和 NT-proBNP 之间的主要生物学区别是 BNP 作为一种激素并且具有生物活性。 相比之下,NT-proBNP 不仅被动排出体外,而且没有生物活性。 因此,NT-proBNP 的半衰期往往比 BNP 更长,后者的半衰期明显更短。 因此,NT-proBNP 在血流中含量丰富,并且在一定程度上以较高水平循环,这表明它对识别早期心力衰竭具有很高的敏感性。
COVID-19 影响分析
COVID-19 大流行封锁期对 BNP 和 NT-proBNP 市场产生了负面影响。 这是由于政府严格控制和限制,心脏病诊断检查的数量减少了。 此外,COVID 期间知识水平低和诊断测试价格高进一步阻碍了市场增长。 然而,COVID-19 也可引起静脉和动脉血栓形成、心律失常和心肌梗塞。 因此,优化心脏病的检测和治疗至关重要,最终会增加床旁 BNP 和 NT-proBNP 检测的使用。
市场增长因素
世界范围内 CAD、AMI 和 CHF 的患病率正在上升
根据全球健康数据交换数据库,目前全球估计有 6434 万充血性心力衰竭 (CHF) 病例。 这相当于 3461.7 亿美元用于医疗保健和 991 万 YLD(因残疾而损失的年数)。 HF 受年龄的影响很大。 此外,心血管问题会显着损害患者的功能能力并增加死亡风险。 因此,正确诊断和治疗这种疾病对于避免重复住院、优化患者预后和提高生活质量至关重要。 因此,心血管疾病在人群中日益流行将为主要市场进入者提供产品投资和商业化机会,从而加速 BNP 和 NT-proBNP 市场的增长。
扩大 BNP 和 NT-proBNP 检测在慢性肾病中的应用
心臟会受到这些变化的影响,随着时间的推移会发展为心肌病和充血性心力衰竭。 这种参与的标誌物包括利钠□,例如 BNP 和 NT-proBNP。 CKD 患者的利钠□水平升高,尤其是透析患者。 BNP 水平随时间的变化已被确定为更准确的 CKD 风险指标。 需要强调的是,肾功能和 NT-pro-BNP 水平在肾功能衰竭中呈高度负相关。 因此,越来越多地使用 BNP 和 NT proBNP 仪表来准确诊断肾功能和治疗 CKD 正在推动市场的扩张。
市场约束
BNP 和 NT-proBNP 测定的不相容性
儘管人们普遍认为这两种测试在临床上基本等效,但在既定的切点上评估了 HF 排除与 BNP 和 NT-proBNP 排除之间的诊断一致性。没有已发表的研究。 在测量患者样本中的 BNP 和 NT-proBNP 时,已经确定了几个因素,例如抗体与其前体 proBNP 的反应性差异、半衰期、肾臟清除率、蛋白质糖基化以及 HF 患者生化多样性的变化。有一些很好的- 已知问题。 因此,很明显 BNP 和 NT-proBNP 不能互换使用。 这增加了这些测试分析的成本并减缓了市场增长。
应用展望
根据应用,BNP 和 NT-proBNP 市场分为心肌梗塞、充血性心力衰竭 (CHF)、急性冠脉综合征 (ACS) 等。 在 2021 年的 BNP 和 NT-proBNP 市场中,充血性心力衰竭部分正在获得可观的增长率。 充血性心力衰竭 (CHF) 是一种轻微的慢性疾病,会损害心肌的收缩能力。 这些指标已被证明可以降低急诊科的成本,并可用于识别心力衰竭,尤其是舒张功能障碍。 BNP 测试的高阴性预测准确性对于排除心力衰竭特别有用。
考察地点前景
根据检测地点,BNP 和 NT-proBNP 市场分为即时检测和实验室检测。 2021 年的 BNP 和 NT-proBNP 市场将由即时检测领域主导。 原因包括更好的资源利用、改善患者的便利性、增加对心臟生物标誌物检测的需求以及改善临床决策。 这也归功于改进了心力衰竭的诊断和治疗。 许多即时检测仪器包括试剂盒、化验、分析仪和测试专用设备。
区域展望
基于区域,对北美、欧洲、亚太地区和 LAMEA 的 BNP 和 NT-proBNP 市场进行了分析。 2021 年,北美地区在 BNP 和 NT-proBNP 市场的收入份额最大。 这可能是由于先进的医疗保健系统以及 BNP 和 NT-proBNP 作为疾病诊断和预后工具的广泛使用。 此外,由于老年人口的增加,对诊断急性心肌梗死等疾病的生物标誌物检测的需求增加,对检测产品的需求也越来越大。 推动该市场扩张的另一个因素是该地区重要公司的集中。
The Global Bnp And Ntprobnp Market size is expected to reach $2.2 billion by 2028, rising at a market growth of 11.4% CAGR during the forecast period.
BNP (B-type natriuretic peptide) & NT-proBNP (N-terminal pro B-type natriuretic peptide) are two extensively used biomarkers that are used to diagnose heart failure and lower ejection fraction, evaluate the effectiveness of therapy, and predict outcomes. As cardiomyocytes stretch, they release proBNP, which breaks down into two circulating fragments. The first fragment is the 32-amino acid C-terminal BNP, and the second fragment is inactive 76-amino acid NT-proBNP.
Both pieces are frequently utilized to aid in detecting heart failure, make predictions about results, and monitor the impact of treatment. The heart produces peptides known as natriuretic peptides. N-terminal pro-B-type natriuretic peptide and Brain natriuretic peptide (BNP) are the two primary forms of these chemicals. BNP & NT-proBNP are typically only detected in trace amounts in the blood.
However, high levels may indicate that the heart isn't supplying the body with enough blood as it requires. Heart failure, sometimes called congestive heart failure, occurs when this happens. Natriuretic peptide assays gauge the blood's levels of NT-proBNP or BNP. Although they employ various parameters, they are both helpful in diagnosing heart failure. The option users will rely on the tools the suggested laboratory of the provider has.
The main biological distinction between BNP & NT-proBNP is that BNP acts as a hormone and is biologically active. In contrast, NT-proBNP is passively excreted from the body as well as is not biologically active. Thus, NT-proBNP tends to have a longer half-life than BNP, which has a significantly shorter half-life. As a result, NT-proBNP circulates in the bloodstream at higher quantities, which suggests that it is more likely to be sensitive for identifying earlier stages of heart failure since it does so at somewhat elevated levels.
COVID-19 Impact Analysis
The COVID-19 pandemic lockdown period had a negative effect on the BNP and NTproBNP market. This is due to stringent governmental controls and limits that resulted in fewer cardiac disease diagnostic tests being performed. In addition, the low level of knowledge and the high price of diagnostic tests during the COVID period further hindered market growth. COVID-19, however, was also capable of causing venous and arterial thrombosis, arrhythmia, and cardiac damage. Thus, optimizing cardiac illness detection and therapy was crucial, which eventually led to a rise in the usage of point-of-care BNP & NT-proBNP testing.
Market Growth Factors
Rising prevalence of CAD, AMI, and CHF around the world
The Global Health Data Exchange database estimates that there is currently 64.34 million congestive heart failure (CHF) cases worldwide. This amounts to USD 346.17 billion spent on healthcare and 9.91 million YLDs (years lost due to disability). HF is significantly influenced by age. Moreover, cardiovascular issues can significantly reduce a patient's functional capacity and raise their mortality risk. Therefore, to avoid repeated hospital stays, optimize patient outcomes, and boost the quality of life, it is crucial to correctly diagnose and treat the disease. As a result, the population's increased prevalence of cardiovascular illness presents an opportunity for leading market participants to invest in and commercialize the products and, in turn, accelerate the growth of the bnp and ntprobnp market.
Growing use of bnp and Ntprobnp assays in chronic kidney disease
The heart is affected by these changes and develops cardiomyopathy and congestive heart failure over time. Markers for this involvement include natriuretic peptides like BNP and NT-proBNP. Natriuretic peptide levels are higher in people with CKD, especially those receiving dialysis. It has been observed that a more accurate risk indicator for CKD is the variations in BNP levels over time. It is important to highlight that renal function and NT-pro-BNP levels are highly inversely correlated in renal failure. Therefore, the increasing use of bnp and ntprobnp assays to diagnose renal function accurately to treat CKD has resulted in market expansion.
Market Restraining Factors
Non-interchangeable nature of bnp and ntprobnp assays
No published investigation had evaluated the diagnostic concordance of BNP & NT-proBNP for ruling out and ruling in HF at the established cut-points, despite the broad recognition that both tests are fundamentally clinically comparable. Measuring BNP or NT-proBNP in patient samples has several well-known problems, such as variable antibody reactivity with the precursor proBNP and changes in half-lives, renal clearance, protein glycosylation, and biochemical variety in HF patients. Hence, it is obvious that BNP and NT-proBNP cannot be used interchangeably. This increases the expense of these test assays and presents factors that will slow down the market's growth.
Application Outlook
Based on application, the Bnp and Ntprobnp market is categorized into myocardial infarction, congestive heart failure (CHF), acute coronary syndrome (ACS), and others. The congestive heart failure segment procured a considerable growth rate in the Bnp and Ntprobnp market in 2021. Congestive heart failure, or CHF, is a gradual, chronic illness that impairs the ability of the heart muscle to contract. These metrics have been demonstrated to reduce costs in the emergency room setting and can be used to identify heart failure, particularly diastolic dysfunction. BNP testing' high negative predictive accuracy is especially useful for excluding heart failure.
Location of Testing Outlook
On the basis of location of testing, the Bnp and Ntprobnp market is divided into point of care testing and laboratory testing. The point of care testing segment acquired the largest revenue share in the Bnp and Ntprobnp market in 2021. Better resource utilization, increased patient convenience, growth in demand for cardiology biomarker testing, and improved clinical decision-making are all credited with this. It also results from improved heart failure diagnosis and treatment. Most point-of-care testing equipment includes kits, assays, analyzers, and devices focused on testing.
Regional Outlook
Based on region, the Bnp and Ntprobnp market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed the maximum revenue share in the Bnp and Ntprobnp market in 2021. This can be ascribed to the advanced healthcare system and the widespread use of BNP and NTproBNP as diagnostic and prognostic disease tools. In addition, the need for testing products is driven by the growing elderly population's need for biomarker testing to diagnose diseases like acute myocardial infarction. Another factor boosting the expansion of this market is the concentration of important companies in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMerieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.
Market Segments covered in the Report:
By Location of Testing
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures